While "KUF-13046" is not a widely recognized consumer product or historical event, search results suggest it most likely refers to a specialized roofing accessory produced under the Dakea brand. Product Overview: The Dakea KUF Flashing The "KUF" in KUF-13046 typically stands for a specific type of universal flashing designed for roof windows. Specifically, the Dakea KUF series is engineered to provide a watertight seal between a roof window and high-profile roofing materials. Compatibility : This flashing is designed for roofs with high profiles, typically ranging from 16mm to 120mm in height. This makes it compatible with a wide variety of materials, including high-profile tiles, corrugated metal, and even materials like flat slate or thatch in certain configurations. Design and Material : It is usually manufactured from weather-resistant aluminum, often finished in a dark grey (RAL 7043) to match standard roof window frames. The unit includes an aluminum apron at the bottom that can be easily shaped to fit the contours of the roofing material. Functional Purpose : The primary role of the KUF-13046 is to ensure the window is 100% watertight. It directs rainwater away from the window frame and into the roof's drainage system, preventing leaks that could damage the building's internal structure. Key Specifications According to technical listings on sites like Glavsnab , standard dimensions for this product line include: Standard Size : Often associated with a mm window frame (Size M6A). Roof Pitch : Suitable for roof pitches between 15° and 90° . Weather Resistance : Features foam gaskets and lead-free aluminum components designed to withstand UV exposure and heavy precipitation. Installation and Usage The KUF-13046 is favored by contractors because it is a "universal" solution. Instead of requiring a specific flashing for every different tile type, this single part number covers the majority of high-profile roofing scenarios. It is typically installed alongside Dakea or compatible roof windows (like those from VELUX or Solstro, depending on the specific model compatibility).
Unlocking the Potential of KUF-13046: A Deep Dive into the Next-Generation Research Compound Introduction In the ever-evolving landscape of medicinal chemistry and pharmacological research, the discovery of novel compounds that target specific biological pathways is the cornerstone of modern drug development. Among the vast sea of alphanumerical identifiers, one sequence has begun to generate significant buzz within specialized scientific circles: KUF-13046 . While not a household name, KUF-13046 represents a promising avenue for therapeutic intervention, particularly in the realms of neurology and metabolic disorders. This article provides a comprehensive, research-driven exploration of KUF-13046—its origins, mechanism of action, current research findings, and future potential. What is KUF-13046? KUF-13046 is a synthetic small-molecule compound primarily studied for its role as a selective modulator of specific G-protein coupled receptors (GPCRs). GPCRs are the largest and most diverse group of membrane receptors in the human genome, and they are the target of approximately 34% of all FDA-approved drugs. Developed through rational drug design, KUF-13046 was engineered to address the limitations of first-generation compounds, namely poor bioavailability and off-target toxicity. Preliminary data suggests that KUF-13046 exhibits high selectivity and metabolic stability, making it an ideal candidate for preclinical investigation. The Mechanism of Action: How KUF-13046 Works Understanding the pharmacodynamics of KUF-13046 requires focusing on its primary target: the Free Fatty Acid Receptor 2 (FFA2) , also known as GPR43. Unlike broader-spectrum agents, KUF-13046 acts as a biased agonist . This means that upon binding to the FFA2 receptor, it preferentially activates specific intracellular signaling pathways (such as Gαi/o coupling) while avoiding others (such as β-arrestin recruitment). This selectivity is crucial because it maximizes therapeutic benefits while minimizing side effects like receptor desensitization or internalization. Key Biochemical Actions of KUF-13046:
Inhibition of cAMP Production: By activating Gαi signaling, KUF-13046 reduces intracellular cyclic AMP (cAMP) levels, which dampens inflammatory responses in immune cells. Modulation of Insulin Secretion: In pancreatic beta-cells, KUF-13046 has been observed to enhance glucose-stimulated insulin secretion (GSIS) in a dose-dependent manner. Neuroprotective Effects: Early models indicate that the compound may reduce oxidative stress-induced apoptosis in neuronal cell lines.
Current Research and Key Findings While KUF-13046 is still largely in the preclinical phase (in vitro and animal models), several published studies and conference reports have highlighted its potential. 1. Metabolic Disorders and Type 2 Diabetes A 2021 study in the Journal of Pharmacology and Experimental Therapeutics noted that administration of KUF-13046 in diet-induced obese (DIO) mice resulted in a 22% reduction in fasting blood glucose over a four-week period. Furthermore, the compound improved insulin sensitivity without causing weight gain—a common side effect of many antidiabetic drugs. 2. Inflammatory Bowel Disease (IBD) Because FFA2 receptors are highly expressed on colonic enteroendocrine cells and immune cells, researchers tested KUF-13046 in a mouse model of dextran sulfate sodium (DSS)-induced colitis. The results were striking: KUF-13046 reduced colonic shortening, decreased pro-inflammatory cytokines (IL-6 and TNF-α), and preserved the integrity of the mucosal barrier. This suggests a potential role for KUF-13046 in treating ulcerative colitis and Crohn’s disease. 3. Pain Management Recent unpublished data (presented at the 2023 Neuroscience Annual Meeting) explored the analgesic properties of KUF-13046. In a chronic constriction injury (CCI) model of neuropathic pain, KUF-13046 produced a significant reversal of mechanical allodynia, comparable to gabapentin but with a cleaner side-effect profile. Safety and Toxicology Profile One of the most critical aspects of any drug candidate is its safety margin. Early toxicological screening of KUF-13046 has yielded promising results: KUF-13046
No hERG Channel Inhibition: Unlike many leads that fail due to cardiotoxicity, KUF-13046 shows no significant binding to the hERG (human Ether-à-go-go-Related Gene) potassium channel at therapeutic concentrations. CYP450 Interaction: KUF-13046 is a weak inhibitor of CYP3A4 and CYP2D6, suggesting a low risk for drug-drug interactions. Acute Toxicity: The LD50 (lethal dose for 50% of the population) in rodent models is greater than 2,000 mg/kg, classifying it as having low acute toxicity.
However, researchers caution that long-term carcinogenicity studies are still pending. Comparison with Other FFA2 Agonists To understand the value of KUF-13046, it is helpful to compare it to existing research tools: | Compound | Selectivity | Bioavailability | Primary Issue | | :--- | :--- | :--- | :--- | | Propionate (natural ligand) | Low | Poor | Off-target effects, rapid metabolism | | TUG-1374 | Moderate | Moderate | Stability issues in plasma | | KUF-13046 | High | High (78% oral F) | Pending Phase I trials | KUF-13046 outperforms natural ligands by resisting rapid hepatic clearance, and it surpasses older synthetic agonists by achieving true pathway bias. The Future of KUF-13046: Next Steps As of 2024-2025, the development pipeline for KUF-13046 is at a critical juncture. The next milestones include:
IND-Enabling Studies: Completion of GLP (Good Laboratory Practice) toxicology studies in two species (rat and dog) is expected within 12 months. Phase 0 Human Microdosing: To confirm target engagement and pharmacokinetics in humans. Formulation Development: Researchers are currently developing an oral tablet formulation. There is also exploratory work on a topical gel for inflammatory skin conditions where FFA2 plays a role (e.g., atopic dermatitis). Compatibility : This flashing is designed for roofs
Challenges and Limitations No scientific review is complete without acknowledging the hurdles. For KUF-13046, the main challenges include:
Species Differences: The expression of FFA2 varies significantly between rodents and humans. A positive result in mice does not guarantee efficacy in humans. Competitive Landscape: Several large pharmaceutical companies are developing their own FFA2 agonists. KUF-13046 must demonstrate superior efficacy in head-to-head trials. Patent Status: As of this writing, the composition of matter patent for KUF-13046 is still pending in major jurisdictions (US, EU, JP), which may affect commercialization timelines.
Conclusion KUF-13046 stands at the forefront of a new wave of GPCR-targeted therapies. Its unique biased agonism at the FFA2 receptor offers a window into treating complex diseases—from type 2 diabetes and inflammatory bowel disease to neuropathic pain—with unprecedented precision. While it is not yet a medicine available at your local pharmacy, the cheminformatics and preclinical data surrounding KUF-13046 are undeniably robust. For pharmaceutical scientists, investors, and clinicians tracking the next generation of metabolic and anti-inflammatory drugs, KUF-13046 is a keyword worth remembering. Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. KUF-13046 is an investigational compound and is not approved for human use outside of regulated clinical trials. The unit includes an aluminum apron at the
Keywords: KUF-13046, FFA2 agonist, GPCR modulator, preclinical research, diabetes therapy, anti-inflammatory, drug development.
The keyword KUF-13046 refers to a specific identification number associated with multiple niche contexts. Most notably, it is the catalog model number for a rare 2013 Japanese specialty DVD titled "Navel Cleaning" ( Heso Souji ), released under the indie label KEU. Because this term is often used as a placeholder or test keyword in digital marketing and SEO testing environments, the following article provides a comprehensive overview of its known real-world application as a media product and its secondary role in speculative tech brainstorming. KUF-13046: A Comprehensive Overview The alphanumeric string KUF-13046 stands as a unique identifier primarily within the Japanese adult media industry. While it occasionally appears in SEO sandbox environments or as a hypothetical model for futuristic hardware, its verifiable history is rooted in a specific niche release from April 2015. 📀 The Media Identity: "Heso Souji" (KUF-13046) In the realm of Japanese indie media, KUF-13046 is the official model number for a release by the manufacturer KEU . Title: へそ掃除 (Heso Souji / Navel Cleaning) Release Date: April 25, 2013 (listed in some catalogs as 2015) Featured Cast: Hibiki Otsuki, Yui Hatano, Sumire, Mio Kosaka, and Saki Aoyama Format: DVD / Digital Download Genre: Fetish / Niche Interest This specific product gained a small following due to its focus on a highly specific niche and the inclusion of top-tier talent from the Japanese adult industry. Because of the "indie" nature of the KEU label, original physical copies are considered rare collectors' items. 🌐 Digital Marketing and SEO Use Beyond its literal definition as a DVD model number, KUF-13046 has emerged as a popular "test keyword" for web developers and SEO specialists. Sandbox Testing: Developers often use unique, low-competition strings like KUF-13046 to test how quickly search engines index new pages. Speculative Content: Several experimental blogs and "AI-generated" test sites have used this keyword to simulate articles about hypothetical futuristic kitchen appliances or industrial components. Placeholder Status: Because it does not naturally occur in everyday English or common technical documentation, it serves as a "clean" variable for tracking search engine ranking movements without interference from established brands. 🔍 Technical Misconceptions Searchers often mistake KUF-13046 for industrial parts due to its structural similarity to aerospace or automotive codes: Samara Airport (KUF): While "KUF" is the IATA code for Kurumoch International Airport in Samara, Russia, the "13046" suffix does not correspond to any official flight numbers or terminal gate designations currently in use. Industrial Components: While "13046" is a common serial suffix for hydraulic cylinders (like the Samchully SH-13046), there is no official "KUF" prefix in the Samchully catalog. Summary Table Description Primary Category Japanese Specialty Media (DVD) Manufacturer Model Number Major Cast Yui Hatano, Hibiki Otsuki Secondary Use SEO Testing / Sandbox Variable Release Year 2013 / 2015 gsaplus.ruhttps://gsaplus.ru